Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumateperone - Intra-Cellular Therapies

Drug Profile

Lumateperone - Intra-Cellular Therapies

Alternative Names: ITI-007; ITI-722

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Intra-Cellular Therapies
  • Class Antidepressants; Antipsychotics; Pyrroles; Quinoxalines; Sleep disorder therapies
  • Mechanism of Action Dopamine receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators; Serotonin 2A receptor antagonists; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Schizophrenia
  • Phase III Behavioural disorders; Bipolar depression
  • Phase II Sleep maintenance insomnia
  • Clinical Phase Unknown Major depressive disorder
  • No development reported Mental disorders; Mood disorders

Most Recent Events

  • 05 Aug 2019 PDUFA action date extended by US FDA to 27/12/2019 for NDA for Schizophrenia
  • 24 Jul 2019 Intra-Cellular Therapies completes a phase III clinical trial in Bipolar depression (Monotherapy) in USA (PO) (NCT02600494)
  • 08 Jul 2019 Efficacy and adverse events data from two phase III (Study 404; Study 401)trials in Bipolar depression released by Intra-Cellular Therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top